AMAM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AMAM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Ambrx Biopharma has the Momentum Rank of 0.
For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.
Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.
For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Thank you for viewing the detailed overview of Ambrx Biopharma's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Cormorant Asset Management, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Margaret Dalesandro | director | ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534 |
Sonja Nelson | officer: Chief Financial Officer | C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BOULEVARD, 3RD FLOOR, FT. LAUDERDALE FL 33301 |
Daniel J. O'connor | director, officer: President and CEO | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
Abhishek Trehan | 10 percent owner | WHITELEY CHAMBERS, DON STREET, ST. HELIER Y9 JE2 4TR |
Darwin Global Master Fund, Ltd. | 10 percent owner | C/O OGIER GLOBAL (CAYMAN) LIMITED, 89 NEXUS WAY, CAMANA BAY, GRAND CAYMAN E9 KY1-9009 |
Paul V Maier | director | 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121 |
Janet Loesberg | director | C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037 |
Kate Hermans | director | C/O AMBRX BIOPHARMA INC., 10975 TORREY PINES ROAD, LA JOLLA CA 92037 |
Xiaowei Chang | director | 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037 |
Stephen C. Glover | director | 108 DOCKSIDE CIRCLE, WESTON FL 33327 |
Andrew Aromando | officer: Chief Operating Officer | C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037 |
Cormorant Private Healthcare Fund Iii Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Cormorant Global Healthcare Master Fund, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Bihua Chen | 10 percent owner | C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
From GuruFocus
By sperokesalga sperokesalga • 04-19-2023
By Business Wire Business Wire • 02-16-2023
By Marketwired • 07-28-2023
By PRNewswire • 01-08-2024
By Marketwired • 08-01-2023
By Business Wire • 01-08-2024
By sperokesalga sperokesalga • 03-27-2023
By Marketwired • 06-28-2023
By PRNewswire • 01-16-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.